INVITROGEN HOLDINGS LIMITED
Get an alert when INVITROGEN HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2027-09-30 (in 1y)
Last filed for 2025-12-31
Confirmation statement due
2027-03-24 (in 10mo)
Last made up 2026-03-10
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£10B
-0.3% vs 2024
Employees
0
Average over period
Profit before tax
-£33M
-11.2% vs 2024
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2025-12-31
| Metric | Trend | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£8,000 | -£25,000 | |
| Profit before tax | -£29,329,000 | -£32,614,000 | |
| Net profit | -£29,329,000 | -£32,614,000 | |
| Cash | — | — | |
| Total assets less current liabilities | £9,568,675,000 | £10,215,828,000 | |
| Net assets | £9,568,675,000 | £9,536,061,000 | |
| Equity | £9,568,675,000 | £9,536,061,000 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Return on capital employed | -0.0% | -0.0% | |
| Current ratio | 0.00x | 0.01x | |
| Interest cover | -0.00x | -0.00x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Mitchell Charlesworth (Audit) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“As of 31 December 2025, the company had net current liabilities of £34,019,000 (2024:£681,172,000). Due to the nature of the company and its operations, there are limited working capital requirements to be met. Notwithstanding, the Directors have considered the cash flows of the company, taking into account expected cash flows as well as considering the terms of intercompany balances and intergroup cash pooling agreements. Thermo Fisher Scientific Inc. has indicated its intention to provide any necessary financial support to enable the company to continue in operational existence for the foreseeable future. To this extent, the directors have received a letter of support from Thermo Fisher Scientific Inc. confirming their financial support for a period of at least twelve months from when these financial statements are authorised for issue. Thus, the directors believe that it is appropriate for the financial statements to be prepared on the going concern basis.”
Group structure
- INVITROGEN HOLDINGS LIMITED · parent
- Invitrogen Europe Ltd 100%
- Erie N2 LLC 100%
- Erie N2 UK Limited 100%
- Erie N10 LLC 100%
- Thermo Fisher Scientific Powder UK Holdings Limited 100%
- Erie UK 4 Limited 100%
- Thermo Fisher Scientific AU Il Limited 100%
- Applied Biosystems International Inc 100%
- Life Technologies Corporation 100%
- Thermo Fisher Scientific Powder Finance LLC 100%
- Thermo Fisher Scientific Powder Financing 2 LLC 100%
- Affymetrix Inc 100%
- Panomics LLC 100%
- eBiosceince Ltd 100%
- Bender MedSystems GmbH 100%
- Affymetrix Japan K.K. 100%
- USB Corporation 100%
- Invitrogen Argentina SA 99.82%
- Life Technologies Clinical Services Lab, Inc 100%
- Thermo Fisher Scientific Colombia S.A.S. 100%
- Compendia Bioscience, Inc 100%
- Invitrogen BioServices India PVT Ltd 99.99%
- Westover Scientific, Inc 100%
- Invitrogen IP Holdings, Inc 100%
- Combinati Incorporated 100%
- Invitrogen Finance Corporation 100%
- Kettlebrook Insurance Co Ltd 100%
- Ion Torren Systems, Inc 100%
- CellzDirect, Inc 100%
- Ambion Inc 100%
- Molecular Probes, Inc 100%
- STC Bio manufacturing, Inc 100%
- Acoustic Cytometry Systems, Inc 100%
- Matrix MicroScience, Inc 100%
- BioTrove Corporation 100%
- BioTrove International, Inc 100%
- Thermo Fisher Scientific Life Technologies Israel Investment I Limited 100%
- Thermo Fisher Scientific Life Technologies Israel Investment II Limited 100%
- Thermo Fisher Israel Ltd 100%
- Gold Cattle Standard Testing Labs, Inc 100%
- Applied Biosystems LLC 100%
- NewCogen PE, LLC 100%
- Erie Finance LLC 100%
- HyClone International Trade (Tianjin) Co Ltd 100%
- Perbio Science, Inc 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2014-05-06 | — | — |
| AHMED, Syed Waqas | Director | 2020-03-23 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2018-10-31 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2018-11-12 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BARLOW, Philip John | Secretary | 2004-03-10 | 2006-05-08 |
| GREGG, Rhona | Secretary | 2015-09-10 | 2026-03-31 |
| MACLEOD, Genoffir Maud | Secretary | 2006-05-08 | 2014-05-06 |
| WARD, Nicola Jane | Secretary | 2014-05-06 | 2014-12-18 |
| OSWALDS OF EDINBURGH LIMITED | Corporate Nominee Secretary | 2004-03-10 | 2004-03-10 |
| BRUST, Bernd | Director | 2004-09-01 | 2009-07-16 |
| COTTINGHAM, John Allen | Director | 2004-03-10 | 2014-02-03 |
| DEUITCH, Dianne Marie | Director | 2010-12-14 | 2012-08-27 |
| GRANT, Lucie Mary Katja | Director | 2014-05-06 | 2019-12-03 |
| GREENAWAY, Monette Rose | Director | 2004-03-10 | 2004-09-01 |
| HADJADJEBA, Lionel Michel | Director | 2009-07-16 | 2009-10-12 |
| INCE, Nicholas | Director | 2015-09-10 | 2018-10-31 |
| MACLEOD, Genoffir Maud | Director | 2014-02-03 | 2014-05-06 |
| NORMAN, David John | Director | 2015-11-16 | 2024-04-18 |
| SMITH, David Harper | Director | 2004-09-10 | 2005-05-01 |
| SOUTER, Thomas Ireland | Director | 2004-03-10 | 2010-11-01 |
| SUTHERLAND, Janet | Director | 2012-08-27 | 2018-11-09 |
| WHEELER, Kevin Neil | Director | 2014-05-06 | 2015-11-16 |
| WINZER, Carl Eric | Director | 2004-03-10 | 2005-05-01 |
| WRIGHT, Katie Rose | Director | 2014-05-06 | 2015-09-04 |
| JORDANS (SCOTLAND) LIMITED | Corporate Nominee Director | 2004-03-10 | 2004-03-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-12-22 | Active |
Filing timeline
Last 20 of 143 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-06 | AA | accounts | Accounts with accounts type full | |
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-03-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-09 | AA | accounts | Accounts with accounts type full | |
| 2025-03-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-06-03 | AA | accounts | Accounts with accounts type full | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-18 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-03-15 | PSC09 | persons-with-significant-control | Withdrawal of a person with significant control statement | |
| 2024-03-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-05-17 | AA | accounts | Accounts with accounts type full | |
| 2023-03-14 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-01-27 | SH01 | capital | Capital allotment shares | |
| 2022-07-13 | AA | accounts | Accounts with accounts type full | |
| 2022-03-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-01-26 | SH01 | capital | Capital allotment shares | |
| 2021-10-11 | AA | accounts | Accounts with accounts type full | |
| 2021-06-17 | SH20 | capital | Legacy |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-12-31 vs 2024-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
-0.3%
£9,568,675,000 £9,536,061,000
-
Employees
—
Not reported
-
Operating profit
-212.5%
-£8,000 -£25,000
-
Profit before tax
-11.2%
-£29,329,000 -£32,614,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers